Stocks Health care ENGN
NASDAQ · Health careenGene Therapeutics Inc. (ENGN)
It posted a net loss of $130.4M. In fiscal 2025 capital spending exceeded operating cash flow by $100.7M. At July 31, 2026 it held $41M in cash. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on September 8, 2026.
Key facts about enGene Therapeutics Inc.
- Net worth
- enGene Therapeutics Inc. has a market value (market cap) of $118.6M at the latest share price, and shareholders' equity of $230.3M on its balance sheet at July 31, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
- Cash flow
- In fiscal 2025 operations used $99.2M of cash.
- Latest report
- The latest periodic report (quarterly report, 10-Q) was filed with the SEC on September 8, 2026 and covers the period to July 31, 2026. Open on SEC EDGAR
- Next earnings report
- enGene Therapeutics Inc.'s next report is expected around December 21, 2026. That is an estimate from its filing rhythm, not a date the company has announced.
What enGene Therapeutics Inc. does
enGene Therapeutics Inc. is registered with the SEC under industry code SIC 2836 (Biological Products, (No Diagnostic Substances)). Its shares trade on NASDAQ under the ticker ENGN.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | n/a | -$117.3M | $2.29 | -$100.7M |
| 2024 | n/a | -$55.1M | $1.46 | -$49.2M |
| 2023 | n/a | -$99.9M | $151.22 | -$25.1M |
| 2023 | n/a | -$24.5M | $44.30 | -$17.7M |
Earnings: every quarter and the next report date
Full financial statements: income, balance sheet and cash flow
Latest SEC filings
What enGene Therapeutics Inc. has filed recently, newest first. Each links to the original document on SEC EDGAR.
- September 8, 2026
- September 8, 2026
- August 14, 2026Passive stake changed SCHEDULE 13G/A
- August 14, 2026Passive stake changed SCHEDULE 13G/A
- August 14, 2026Passive stake changed SCHEDULE 13G/A
- August 13, 2026Passive stake changed SCHEDULE 13G/A
- August 12, 2026Passive stake changed SCHEDULE 13G/A
- August 11, 2026Other event 8-K
- July 22, 2026Passive stake (5% or more) SCHEDULE 13G
- July 17, 2026
Insider trades
What the people running enGene Therapeutics Inc. did with its shares, from the Form 4 filings they must send the SEC within two business days.
Insiders bought $10.1K worth of shares on the open market in the last 90 days and sold none.
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| September 22, 2026 | Grossman WilliamInterim Chief Medical Officer, Director | Bought | 5,102 | $10.1K |
Who owns ENGN
Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.
5% holders
| Holder | Of class | Filed |
|---|---|---|
| Perceptive Advisors LLC13G, passive with 2 related filers | 9.99% | August 14, 2026 |
| BML Investment Partners, L.P.13G, passive | 9.95% | May 14, 2026 |
| Lumira Capital Investment Management Inc.13D, may seek influence with 19 related filers | 9.6% | February 21, 2024 |
| Raymond Debbane13G, passive with 7 related filers | 9.3% | August 13, 2026 |
| Anders Hove13G, passive with 4 related filers | 5% | July 22, 2026 |
Largest institutional holders
Positions that investment managers reported on Form 13F for the quarter ended June 30, 2026, largest first, with the change on the quarter ended March 31, 2026. Managers file 13F up to 45 days after a quarter ends. 60 managers reported a position.
| Holder | Shares | Change on quarter |
|---|---|---|
| Fcpm III Services B.V. | 9,632,561 | 0 |
| BML Capital Management, LLC | 6,669,908 | new |
| Siren, L.L.C. | 6,256,662 | +1,003,503 |
| Perceptive Advisors LLC | 4,822,169 | -1,005,337 |
| Ameriprise Financial Inc | 2,675,876 | new |
| Nextech Invest Ltd. | 2,324,943 | 0 |
| ADAR1 Capital Management, LLC | 2,104,986 | +1,971,300 |
| Vestal Point Capital, LP | 1,667,430 | -497,570 |
| Acorn Capital Advisors, LLC | 1,271,257 | new |
| Peapod Lane Capital LLC | 1,102,149 | new |
| Balyasny Asset Management L.P. | 1,007,344 | -141,653 |
| Millennium Management LLC | 966,627 | +6,946 |
| Omega Fund Management, LLC | 876,357 | 0 |
| Renaissance Technologies LLC | 829,700 | +673,600 |
| SR One Capital Management, LP | 747,750 | 0 |
| Citadel Advisors LLC | 717,686 | +563,744 |
| Affinity Asset Advisors, LLC | 600,000 | -10,370 |
| UBS Group AG | 509,087 | +496,070 |
| Quadrature Capital Ltd | 478,070 | +444,273 |
| Eversept Partners, LP | 469,584 | -40,959 |
Insiders
1 insiders reported holding 5,102 shares in total, about $8.5K at the last price.
| Holder | Shares |
|---|---|
| Grossman WilliamInterim Chief Medical Officer, Director | 5,102 |
Questions about ENGN
What does enGene Therapeutics Inc. do?
enGene Therapeutics Inc. is a company in the Health care sector, listed on NASDAQ as ENGN. Its shares trade on NASDAQ under the ticker ENGN.
What is enGene Therapeutics Inc.'s net worth?
enGene Therapeutics Inc. has a market value (market cap) of $118.6M at the latest share price, and shareholders' equity of $230.3M on its balance sheet at July 31, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
Is enGene Therapeutics Inc. profitable?
No. Over the twelve months to July 31, 2026 it reported a net loss of $130.4M.
When did enGene Therapeutics Inc. last report?
Its most recent periodic report is the quarterly report (10-Q) filed on September 8, 2026. It covers the period to July 31, 2026. Its newest filing of any kind is the insider trade from September 24, 2026.
When is enGene Therapeutics Inc.'s next earnings report?
enGene Therapeutics Inc.'s next report is expected around December 21, 2026. That is an estimate from its filing rhythm, not a date the company has announced.
Similar companies
Compare ENGN with
Follow ENGN
Get an email when enGene Therapeutics Inc. files with the SEC: results, executive changes, material agreements and annual reports.
Where the numbers come from
Financial figures are the values enGene Therapeutics Inc. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.